During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell ...

Burkitt lymphoma, a cancer that impacts a subset of immune cells called B cells, develops most often in children and young adults.  Patients with Burk | Cancer ...

Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

A patient with heavily pretreated relapsed/refractory diffuse large B-cell lymphoma achieved complete remission following ...

Chronic lymphocytic leukemia (CLL) cell–derived exosomes demonstrated the ability to alter healthy donor cell function and suppress normal blood cell formation. These particles affected monocytes, ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Clinical data on a CD19-directed CAR-T cell therapy in lupus has sent interest in the depletion of B cells to treat autoimmune and inflammatory diseases into overdrive in recent years. Companies ...

a clinical-stage biotechnology pioneer redefining in vivo cell engineering through its proprietary Vivoexpress platform, announced groundbreaking clinical data from its noval in vivo CD19 CAR-T ...

TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.